David Shaw’s Travere Therapeutics TVTX Stock Holding History

David Shaw’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-20,000	Closed	-$421K	–	3782
2017 Q4	$421K	Hold	20,000	–	–	﹤0.01%	3081
2017 Q3	$498K	Hold	20,000	–	–	﹤0.01%	2908
2017 Q2	$388K	Hold	20,000	–	–	﹤0.01%	2924
2017 Q1	$369K	Sell	20,000 -40,000	-67%	-$782K	﹤0.01%	2882
2016 Q4	$1.14M	Hold	60,000	–	–	﹤0.01%	2383
2016 Q3	$1.34M	Hold	60,000	–	–	﹤0.01%	2194
2016 Q2	$1.07M	Buy	60,000 +10,000	+20%	+$162K	﹤0.01%	2376
2016 Q1	$683K	Buy	+50,000	New	+$759K	﹤0.01%	2597

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's TVTX Position: Q2 2026 in Review

David Shaw increased its Travere Therapeutics (TVTX) stake by 72% in Q2 2026, buying an estimated $26.8M and bringing the position to 1,440,469 shares worth $81.8M. The position accounts for 0.04% of the portfolio, ranked #532.

David Shaw first reported a position in TVTX in Q1 2014 and has held it in 48 quarters since. 317 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

David Shaw held 1,440,469 shares of Travere Therapeutics worth $81.8M as of Q2 2026.
David Shaw bought 603,925 Travere Therapeutics shares in Q2 2026, an estimated $26.8M.
Travere Therapeutics made up 0.04% of David Shaw's portfolio in Q2 2026, its #532 holding.
David Shaw first reported a position in Travere Therapeutics in Q1 2014 and has held it in 48 quarters since.
317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.